Alpha Tau Medical
Peter Melnyk has a vast work experience in the pharmaceutical industry. Peter is currently the Chief Commercial Officer and a Member of the Board of Directors at Alpha Tau Medical. Previously, they served as the CEO of Fortovia Therapeutics from June 2019 to September 2022. Before that, they worked as a Principal at Targeted Pathways from January 2018 to May 2019. Prior to that, Peter held the position of Chief Commercial Officer at Novocure from September 2011 to December 2017. Peter also served as the Senior Vice President of Global Sales and Marketing at OSI Pharma/Astellas Pharma US from June 2005 to June 2011. Earlier in their career, Peter held various leadership roles at OSI Pharmaceuticals Inc, Pfizer, and Pharmacia/Pfizer. Peter started their career in the pharmaceutical industry at Bristol-Myers Squibb in the field of Oncology, where they worked from 1991 to 2000.
Peter Melnyk attended McGill University from 1982 to 1998. No specific degree or field of study information was provided.
This person is not in any offices
Alpha Tau Medical
Alpha Tau Medical (https://www.alphatau.com/) focuses on research, development and commercialization of Alpha DaRT (Diffusing Alpha-Emitters Radiation Therapy) for the treatment of solid cancer tumors. Initially developed at Tel Aviv University, Alpha DaRT was shown to be effective and safe for treating different types of cancer in multiple animal studies. The company is running its first clinical trial in several sites in the EU and is currently commencing clinical trials at over 55 leading cancer centers worldwide.